Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/BRAF_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BRAF_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BRAF_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/BRAF_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BRAF_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/BRAF_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BRAF_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BRAF_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BRAF_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00071735 | Colorectum | CRC | epidermal growth factor receptor signaling pathway | 39/2078 | 108/18723 | 6.90e-12 | 5.90e-09 | 39 |
GO:00381275 | Colorectum | CRC | ERBB signaling pathway | 41/2078 | 121/18723 | 2.12e-11 | 1.59e-08 | 41 |
GO:00181054 | Colorectum | CRC | peptidyl-serine phosphorylation | 61/2078 | 315/18723 | 9.88e-06 | 3.31e-04 | 61 |
GO:00901505 | Colorectum | CRC | establishment of protein localization to membrane | 51/2078 | 260/18723 | 3.59e-05 | 9.05e-04 | 51 |
GO:00182093 | Colorectum | CRC | peptidyl-serine modification | 62/2078 | 338/18723 | 4.67e-05 | 1.10e-03 | 62 |
GO:00347642 | Colorectum | CRC | positive regulation of transmembrane transport | 44/2078 | 219/18723 | 6.68e-05 | 1.45e-03 | 44 |
GO:00442622 | Colorectum | CRC | cellular carbohydrate metabolic process | 49/2078 | 283/18723 | 1.06e-03 | 1.24e-02 | 49 |
GO:0043410 | Colorectum | CRC | positive regulation of MAPK cascade | 72/2078 | 480/18723 | 4.85e-03 | 3.74e-02 | 72 |
GO:00434105 | Endometrium | AEH | positive regulation of MAPK cascade | 84/2100 | 480/18723 | 2.19e-05 | 4.25e-04 | 84 |
GO:009015010 | Endometrium | AEH | establishment of protein localization to membrane | 51/2100 | 260/18723 | 4.74e-05 | 7.85e-04 | 51 |
GO:001003816 | Endometrium | AEH | response to metal ion | 65/2100 | 373/18723 | 2.02e-04 | 2.54e-03 | 65 |
GO:00071739 | Endometrium | AEH | epidermal growth factor receptor signaling pathway | 24/2100 | 108/18723 | 7.57e-04 | 7.20e-03 | 24 |
GO:00381279 | Endometrium | AEH | ERBB signaling pathway | 26/2100 | 121/18723 | 7.99e-04 | 7.54e-03 | 26 |
GO:00515927 | Endometrium | AEH | response to calcium ion | 28/2100 | 149/18723 | 4.22e-03 | 2.79e-02 | 28 |
GO:00181058 | Endometrium | AEH | peptidyl-serine phosphorylation | 50/2100 | 315/18723 | 7.20e-03 | 4.13e-02 | 50 |
GO:004341011 | Endometrium | EEC | positive regulation of MAPK cascade | 89/2168 | 480/18723 | 4.21e-06 | 1.08e-04 | 89 |
GO:009015015 | Endometrium | EEC | establishment of protein localization to membrane | 52/2168 | 260/18723 | 5.46e-05 | 8.64e-04 | 52 |
GO:001003817 | Endometrium | EEC | response to metal ion | 66/2168 | 373/18723 | 2.86e-04 | 3.23e-03 | 66 |
GO:000717313 | Endometrium | EEC | epidermal growth factor receptor signaling pathway | 24/2168 | 108/18723 | 1.18e-03 | 1.00e-02 | 24 |
GO:003812713 | Endometrium | EEC | ERBB signaling pathway | 26/2168 | 121/18723 | 1.28e-03 | 1.06e-02 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRAF | SNV | Missense_Mutation | novel | c.335N>G | p.Ser112Cys | p.S112C | P15056 | protein_coding | deleterious(0.04) | possibly_damaging(0.846) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
BRAF | SNV | Missense_Mutation | | c.1345N>A | p.Asp449Asn | p.D449N | P15056 | protein_coding | tolerated(0.67) | possibly_damaging(0.876) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BRAF | SNV | Missense_Mutation | | c.2093A>G | p.Lys698Arg | p.K698R | P15056 | protein_coding | deleterious(0.01) | benign(0.011) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRAF | SNV | Missense_Mutation | novel | c.1297N>A | p.Glu433Lys | p.E433K | P15056 | protein_coding | tolerated(0.22) | benign(0.04) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
BRAF | SNV | Missense_Mutation | | c.1610T>C | p.Leu537Ser | p.L537S | P15056 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
BRAF | SNV | Missense_Mutation | | c.1040N>T | p.Arg347Leu | p.R347L | P15056 | protein_coding | tolerated(0.18) | benign(0.224) | TCGA-E2-A1B5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
BRAF | SNV | Missense_Mutation | novel | c.1706N>A | p.Ala569Asp | p.A569D | P15056 | protein_coding | deleterious(0) | benign(0.265) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
BRAF | insertion | Nonsense_Mutation | novel | c.267_268insAATAAGTAACTTGTTCTTGTCCGTCATACTCCCAGTTTAACAATT | p.Leu89_Asp90insAsnLysTerLeuValLeuValArgHisThrProSerLeuThrIle | p.L89_D90insNK*LVLVRHTPSLTI | P15056 | protein_coding | | | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BRAF | insertion | Frame_Shift_Ins | novel | c.2146_2147insCACCTCGCCGGCCTGGTTTTTATTT | p.Leu716ProfsTer37 | p.L716Pfs*37 | P15056 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRAF | SNV | Missense_Mutation | | c.1202N>T | p.Thr401Ile | p.T401I | P15056 | protein_coding | tolerated(0.08) | benign(0.026) | TCGA-EA-A1QT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | TRAMETINIB DIMETHYL SULFOXIDE | | 25435907,28480077,28078132 |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | DUAL IGF-1R/INSR INHIBITOR BMS-754807 | | 25527633 |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | AMG 232 | | 25567130 |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | PLX3397 | PEXIDARTINIB | 25939769 |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | PLX7904 | | 26466569,27523909 |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | PLX8394 | PLX8394 | 27834212,24422853 |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | Vemurafenib | VEMURAFENIB | |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | Pimasertib | PIMASERTIB | 23629727 |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | vemurafenib | VEMURAFENIB | |
673 | BRAF | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME | | GSK2126458 | OMIPALISIB | 22389471 |